Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas.
The purpose of the study was to evaluate the prognostic role of the DNA repair protein APE/Ref-1 in breast carcinomas. Immunohistochemical analysis for APE/Ref-1 was performed in a series of 133 consecutive stage I-III breast carcinomas. The relationship between APE/Ref-1 and other prognostic and predictive factors such as tumor size, nodal status, histologic grade, p53 expression, hormonal receptor status, vascular invasion and necrosis was investigated. The prognostic value of APE/Ref-1 was studied by univariate and multivariate analysis. The predominant pattern of APE/Ref-1 immunohistochemical expression was nuclear, although cytoplasmic and mixed nuclear/cytoplasmic localization was also observed. The percentage of cells with APE/Ref-1 cytoplasmic stain directly correlated with the percentage of p53 positive cases (rho=0.28, p=0.013). The small group of women whose tumors showed mixed nuclear/cytoplasmic APE/Ref-1 localization (n=5) experienced a significantly poorer survival (p=0.014) and Cox proportional hazard model analysis identified APE/Ref-1 as an independent prognostic factor. The results suggest that subcellular localisation of APE/Ref-1 may influence the aggressiveness of breast carcinomas.
Puglisi
Fabio
F
Clinica Oncologica, Policlinico Universitario, Piazzale S.M. Misericordia I-33100 Udine, Italy. fabio.puglisi@med.uniud.it
Barbone
Fabio
F
Tell
Gianluca
G
Aprile
Giuseppe
G
Pertoldi
Barbara
B
Raiti
Concetta
C
Kelley
Mark R
MR
Damante
Giuseppe
G
Sobrero
Alberto
A
Beltrami
Carlo Alberto
CA
Di Loreto
Carla
C
D000230:Adenocarcinoma / Q000175:diagnosis / Q000201:enzymology* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000175:diagnosis / Q000201:enzymology* / Q000401:mortality; D019757:Carbon-Oxygen Lyases / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000201:enzymology* / Q000401:mortality; D018275:Carcinoma, Lobular / Q000175:diagnosis / Q000201:enzymology* / Q000401:mortality; D004260:DNA Repair; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase; D004706:Endodeoxyribonucleases / Q000378:metabolism*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007558:Italy / Q000453:epidemiology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D011960:Receptors, Estrogen; D016159:Tumor Suppressor Protein p53; D004706:Endodeoxyribonucleases; D019757:Carbon-Oxygen Lyases; C085108:APEX1 protein, human; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase